Company Interview / Cyclopharm (ASX: CYC) Investor Presentation

Cyclopharm (ASX: CYC) is a global nuclear medicine and molecular imaging provider. Its leading imaging product Technegas is revolutionary technology used in pulmonary diagnostic imaging and patient management across the world.

CEO James McBrayer takes us through Technegas' FDA approval in the United States, and its ambitions for the company to expand into the American market. In addition to FDA approval in the US, it is in trials in France and is now available in 66 countries.

James McBrayer asserts that there's no competition in sight, positioning Cyclopharm to capitalise on emerging technologies in imaging and analytics

Listen to Cylophram chief executive and managing director, James McBrayer for more.

You should be aware that companies presenting do so under commercial agreement with AUSBIZ CAPITAL PTY LTD